Innovative Cancer Theraputics

1. Presentation by
Darren Cunningham
CEO
dcunningham@inflectionbio.com

2. 2
Overview
1 in 3 will get cancer – many will not survive
***
Our mission
develop groundbreaking new treatments for those
suffering with cancer

3. 3
Business Model
DISC TARGET HITS LEAD
PRE-
CLIN
IND PHASE 1 PHASE 2 PHASE 3 APP LAUNCH
LEAD
IND
PACKAGE
EARLY
CLINICAL
PRE-
CLINICAL
10-15 YEAR DEVELOPMENT
Value Inflection:
LICENSE IN PARTNER/
EXIT/IPO
4 – 5 YEAR DEVELOPMENT

4. 4
Phase I Value Creation Potential
Phase I
Oncology
Exits
$100m -
>$300m

5. 5 Spanish National Cancer Research Centre
Collaboration with CNIO - June 2013

6.  Comprising first-in-class agents protected by composition
of matter patents
6
Pipeline – Targeted Therapeutics
RESEARCH PRE-CLIN IND PHASE ITARGET
MULTIPLE MYELOMA
NSCLC
IBL-202 (PIM/PI3K)
IBL-300s (PIM/PI3K/mTOR)
HAEM MALIGNANCIESIBL-100s (Pan-PIM)
OTHER K-RAS TUMOURS
B-CELL LYMPHOMAS
B-CELL LYMPHOMAS
Secure Partner after
Phase I
Secure Partner at IND

7. 7
PIM Kinase a driver of resistance in AKT/PI3K
1. PIM expression dramatically
elevated by PI3K/AKT pathway
inhibition
2. PIM mediates feedback loop
driving acquired resistance to a
number of treatment modalities.
Underpins rationale for co-
targeting PI3K and PIM;
huge clinical opportunity

8. 8
IBL-300s – Targeting Molecular Subsets in NSCLC(Stage IV)
EGFR TKI ResistantMutant K-RasDe novo PI3k activation
Lung cancer leading cause of cancer death (1.6m ww)
- NSCLC ~80% = $10bn market by 2020
Role for PI3K and PIM co-targeting in NSCLC Rationale for IBL-300s
 NSCLC - K-Ras mutated
in 15-30%
 Downstream activation
include
PI3K/AKT/mTOR
 PIM inhibition shuts
down growth in mutant
K-Ras NSCLC cell lines
 NSCLC - EGFR
mutations in ~10% de
novo
 Cancer recurs (~12mo)
with ~10% due to PI3K
activation
 PIM elevated in EGFR
TKI resistant lines
 Squamous cc – PIK3CA/
PTEN mutations ~30%
 PIM and PI3K inhibitors
act synergistically in vitro
and in vivo
 PIM mediates PI3K/AKT
resistance

9. 9
Research Collaboration Network
 Network spanning US, EU, Australia
 NSCLC, pancreatic, ovarian, multiple myeloma, DLBCL,
MCL, CLL, neuroblastoma, breast cancer, mechanistic

10. Leadership
Darren
Cunningham
CEO
15 year record
in licensing,
M&A, IP,
fundraising, IR
Amarin, Elan,
PWC
B. Comm, M.
Acc, FCA
Dr. Michael
O’Neill
Director R&D
22 year drug
discovery and
development
 Eli Lilly,
Almirall, Merck
 BA
Psychology,
PhD
MANAGEMENT ONCOLOGY ADVISORY PANEL
Prof. Josep
Tabernero
 Director, Vall
d’Hebron Institute of
Oncology
 Led clinical
development of
PI3K pathway
inhibitors
 ESMO Executive
Board
Prof. Funda
Meric-Bernstam
 Professor of
Surgical Oncology;
and
 Chair Department
of Investigational
Cancer
Therapeutics, M.
D. Anderson
Cancer Center
Dr. Martin Page
 30+ years
experience in
oncology R&D
 Previous VP, Global
Head of Oncology
Res. J&J
 Roles with OSI
Pharma, Oxford
Glycosciences, and
Glaxo-Wellcome

11.  Incorporated 2012
 Headquartered in Dublin, with base in London
 2 full time employees
– Internship program, 3 in 2015
– PhD in TCD via Innovation Partnership
 6 board members; panel of international scientific
advisors
 6 CROs (UK, France, China, India)
 >10 research collaborations (US, Ireland, UK,
Germany, Sweden, Australia)
 ~€2.2m raised to date (EI, VC and privates)
11
Corporate profile

12. Thank you
Darren Cunningham
dcunningham@inflectionbio.com